Press Releases

Date	Title	PDF Version
Dec 21, 2018	Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dec 03, 2018	Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
Nov 20, 2018	Alexion to Present at the Evercore ISI Healthcare Conference
Nov 07, 2018	Alexion to Present at Credit Suisse’s 27th Annual Healthcare Conference
Nov 02, 2018	Alexion Completes Acquisition of Syntimmune
Nov 01, 2018	Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting
Oct 24, 2018	Alexion Reports Third Quarter 2018 Results
Oct 24, 2018	Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases
Oct 04, 2018	Alexion to Report Third Quarter 2018 Results on Wednesday, October 24, 2018
Sep 26, 2018	Alexion to Acquire Syntimmune

Search